CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Selumetinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03213691
NCT03213691Phase 2Completed
CompareCT.gov

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

National Cancer Institute (NCI)·interventional·Posted Jul 11, 2017·Updated Feb 5, 2025

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Selumetinib, and 1 other intervention for Advanced Malignant Solid Neoplasm and 10 related conditions. Completed, enrolled 21 participants across 110 sites in 2 countries.

Detailed Summary

This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to other places in the body and have come back or do not respond to treatment. Selumetinib sulfate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 11, 2017
Enrollment StartOct 30, 2017
Primary CompletionJun 30, 2021
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.0 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Selumetinibdrug

Given PO

Selumetinib Sulfatedrug

Given PO